We provide semaglutide tablets, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/oem-odm/tablet/semaglutide-tablets-7mg.html
1.We supply
(1)Tablet
(2)Gummies
(3)Capsule
(4)Spray
(5)API(Pure powder)
(6)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-029
Semaglutide CAS 910463-68-2
Analysis: HPLC, LC-MS, HNMR
Novo Nordisk releases ORION data: Simeglutide tablets significantly reduce weight compared to orforglipron
On April 3, 2026, Novo Nordisk will present the ORION research results at the annual meeting of the Obesity Medicine Association in San Diego. This study showed that in a population adjusted indirect treatment comparison, Wegovy @ (semaglutide) tablets 25 mg showed significantly higher average weight loss compared to orforglipron 36 mg. It is worth noting that the FDA has recently approved the marketing of orforglipron under the trade name "Foundayo", with a maximum approved dose range of 17.2 mg. This 17.2 mg tablet is equivalent to the dose of orforglipron 36 mg capsule used in the Phase 3 clinical study and serves as the control drug for the ORION study. In addition, another patient preference study showed that adult overweight or obese patients prefer treatment features similar to semaglutide tablets. The above results suggest potential differences and provide useful references for clinical decision-making.
Simeglutide vs orforglipron
The ORION study is a population adjusted indirect treatment comparison (ITC) that evaluates the weight loss efficacy and tolerability of semaglutide tablets 25 mg and orforglipron 36 mg based on Phase 3 OASIS 4 and ATTAIN-1 clinical trial data. The study used a simulated treatment comparison method to evaluate the percentage change in weight from baseline; In terms of tolerability outcomes (including discontinuation of treatment due to any adverse events and gastrointestinal adverse events), a two-stage matching adjustment indirect comparison method is used. The analysis adjusted for baseline weight, blood glucose status, and gender.
Ganli Pharmaceutical GLP-1 biweekly formulation authorized by JW Pharmaceutical in South Korea
On April 8, 2026, Ganli Pharmaceutical Co., Ltd. (hereinafter referred to as Ganli Pharmaceutical, stock code: 603087. SH) announced its partnership with a leading pharmaceutical company in South Korea! Pharmaceutical (hereinafter referred to as JW Pharmaceutical) has signed an exclusive license agreement, and the two parties will cooperate on the clinical development, registration application, and commercialization of the bi weekly preparation of glucagon like peptide-1 receptor agonist (GLP-1 RA) independently developed by Ganli Pharmaceutical - Bofan and Gruptide Injection (R&D code: GZR18) in South Korea.
According to the agreement, the pharmaceutical company will obtain exclusive rights to develop and commercialize Bofangrupeptide injection in South Korea. Ganli Pharmaceutical will receive a one-time, non refundable down payment of $5 million, and may collect milestone payments totaling $76.1 million based on research and development progress, regulatory approvals, and commercialization, as well as tiered royalty fees based on net sales after product commercialization; The potential total transaction amount is as high as $81.1 million (excluding royalties).
This cooperation is the third overseas authorization of Ganli Pharmaceutical's Bofangulutide Injection after cooperation in Latin America and India. According to Grand View Research data, the GLP-1RA market in the Asia Pacific region is expected to reach $5.47 billion by 2025 and grow to $16.95 billion by 2033, with a compound annual growth rate of 14%, making it one of the fastest-growing regions in the world. At present, the penetration rate of GLP-1 drug therapy is extremely low, and there is huge room for growth. As a mature market in the Asia Pacific region, South Korea's GLP-1RA market is expected to reach $526 million by 2025 and is projected to increase to $1.6 billion by 2033. The South Korean market has a high acceptance of innovative drugs and strong patient payment capabilities, making it a strategic location for multinational pharmaceutical companies to enter the East Asian market. The global map of Ganli Pharmaceutical's GLP-1RA biweekly formulation, Bofangulotide, is accelerating.
Weicheng Pharmaceutical has completed a $54 million Series A financing to accelerate the promotion of extrahepatic delivery of small nucleic acid therapy
On April 10, 2026, Vivatides Therapeutics announced the completion of an oversubscribed $54 million Series A funding round. This round of financing is led by Qiming Venture Capital and a well-known industry fund, jointly invested by Honghui Fund, a well-known investment fund, and Taifu Capital. The original investor Xingze Capital continues to increase its investment. Weicheng Pharmaceutical focuses on the research and development of targeted small nucleic acid drugs outside the liver. The funds raised in this round of financing will mainly be used for the iterative optimization of the company's core extrahepatic delivery technology platform, the clinical promotion of multiple pipelines, as well as team expansion and the construction of a global research and development network.
Traditional small nucleic acid drugs are limited by delivery technology and mostly focus on liver targeting, while the treatment needs of extrahepatic tissue related diseases have not been met for a long time, becoming a breakthrough direction for the next generation of technology. With the rise of extrahepatic delivery technology, the indications for small nucleic acid drugs are rapidly expanding from rare diseases to chronic diseases such as hyperlipidemia, hypertension, and tumors.
After this round of financing, the company will further accelerate the optimization of preclinical pipelines and prepare for IND applications, while continuously expanding its research and development and management teams, and deepening the platform construction of extrahepatic delivery technology. In the future, the company will focus on meeting the unmet clinical needs, focus on the field of extrahepatic diseases with high incidence rate and high demand, build an extrahepatic small nucleic acid drug research and development enterprise, and provide more efficient and safer innovative therapies for patients around the world.